Eskinor-F - Instructions For Use, Reviews, Price Of Tablets, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Eskinor-F

Eskinor-F: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. For violations of liver function
12. 12. Drug interactions
13. 13. Analogs
14. 14. Terms and conditions of storage
15. 15. Terms of dispensing from pharmacies
16. 16. Reviews
17. 17. Price in pharmacies

Latin name: Eskinor-F

ATX code: G03AC03

Active ingredient: levonorgestrel (Levonorgestrel)

Manufacturer: Famy Care, Limited (India)

Description and photo update: 2020-18-04

Eskinor-F is a drug for emergency postcoital contraception.

Release form and composition

The drug is admitted in the form of tablets: white or almost white, round, biconvex (at a dosage of 0.75 mg: 2 pcs. In blisters, in a cardboard box 1 blister; in a dosage of 1.5 mg: 1 pc. In blisters, blister in a cardboard box 1. Each box also contains instructions for the use of Eskinor-F).

1 tablet contains:

• active substance: levonorgestrel - 0.75 or 1.5 mg;
• auxiliary components: potassium polacrilin, lactose in granules [corn starch, lactose, sucrose (sucrose)], magnesium stearate.

Pharmacological properties

Pharmacodynamics

Eskinor-F is a drug for emergency contraception. Its active substance, levonorgestrel, is a synthetic progestogen, has a contraceptive effect and a pronounced progestin and antiestrogenic efficacy. The use of the recommended dosing regimen ensures the suppression of ovulation and fertilization during sexual intercourse that occurred in the pre-ovulation phase, when the probability of conception is highest. In addition, by increasing the viscosity of the cervical secretion, levonorgestrel interferes with the movement of sperm. It is capable of causing changes in the endometrium that prevent the implantation of a fertilized egg. But if the implantation has already taken place, then the drug is not effective.

Receiving Escinor-F within the first 24 hours after unprotected intercourse provides a contraceptive effect in 95% of women, in the period from 24 to 48 hours - 85%, from 48 to 72 hours - only 58%. The effectiveness of levonorgestrel decreases as the time between intercourse and drug administration increases. In this regard, it is recommended to take the pill as soon as possible after unprotected sex.

Therapeutic doses of levonorgestrel do not significantly affect blood coagulation factors, fat and carbohydrate metabolism.

Pharmacokinetics

After oral administration, levonorgestrel is almost completely and rapidly absorbed. Absolute bioavailability - 100%. The maximum concentration (C _max) of levonorgestrel in the blood plasma against the background of the taken tablet at a dosage of 0.75 mg is achieved after 1.6 hours and is 14.1 ng / ml. When using a tablet at a dosage of 1.5 mg, C _max in blood plasma of 18.5 ng / ml is achieved after 2 hours. After reaching C _{max, the} level of levonorgestrel concentration decreases.

It binds to SHBG (sex hormone binding globulin) and blood plasma albumin. With SHBG at 65% of the dose taken, and only 1.5% of levonorgestrel is in free form.

Penetrates into breast milk.

Levonorgestrel is metabolized in the liver by hydroxylation to form pharmacologically inactive metabolites, which are excreted in the form of conjugated glucuronides. The process corresponds to the biotransformation of sex hormones.

It is excreted in the form of metabolites through the kidneys and intestines in approximately equal proportions. The half-life is approximately 26 hours.

Indications for use

The use of Eskinor-F is indicated exclusively as an emergency contraceptive. The pills are taken after unprotected sex or if the contraceptive method used is unreliable.

Contraindications

Absolute:

• severe liver failure;
• lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome;
• suspected or established pregnancy;
• period of breastfeeding;
• age under 16;
• hypersensitivity to the components of the drug.

Caution should be exercised when taking Eskinor-F tablets for women with a history of pelvic inflammatory disease or ectopic pregnancy, liver or biliary tract diseases, jaundice (including history), Crohn's disease and other pathologies of the gastrointestinal tract (GIT), presence predisposition (hereditary or acquired) to thrombosis, overweight.

Eskinor-F, instructions for use: method and dosage

Eskinor-F tablets are taken orally after unprotected intercourse or in the absence of confidence in the reliability of the contraceptive method used (but no later than 72 hours later), at any period of the menstrual cycle.

Repeated use of the emergency contraceptive drug during one menstrual cycle is contraindicated due to the increased risk of acyclic bleeding or bleeding.

Women with an irregular menstrual cycle can use Eskinor-F only if they are confident that there is no pregnancy.

Recommended dosage:

• 0.75 mg tablets: a reliable contraceptive effect is provided by the following scheme of administration - 1 tablet within a specified period of time after unprotected sexual intercourse, then 12 hours after taking the first tablet (but no later than 16 hours), you should take the second tablet from the package;
• 1.5 mg tablets: 1 tablet as soon as possible after unprotected intercourse.

If vomiting occurs within three hours after taking any of the doses of the drug, an additional pill must be taken.

After using Escinor-F, condoms, a cervical cap and other barrier methods of contraception should be used before the next menstruation.

Side effects

• very often: abdominal pain, tiredness, nausea, acyclic spotting (bleeding);
• often: vomiting, diarrhea, soreness and / or tension of the mammary glands, heavy menstrual bleeding, dysmenorrhea, delayed menstruation for 5–7 days, dizziness, headache;
• possible: development of allergic reactions - rash, itching, hives, swelling of the face.

Overdose

Symptoms: nausea, vomiting, spotting, or bleeding.

Treatment: the specific antidote of levonorgestrel is unknown, so symptomatic therapy is indicated.

special instructions

Eskinor-F is not an alternative drug to permanent methods of contraception. It should be borne in mind that the contraceptive effect of levonorgestrel decreases with every hour of delay in taking the pill during the first 72 hours after unprotected intercourse.

In most women, the nature of the menstrual cycle does not change while taking Escinor-F.

In some cases, levonorgestrel is able to potentiate the appearance of acyclic spotting. If menstruation is delayed by more than 5-7 days or the nature of the discharge changes, it is necessary to exclude the presence of pregnancy. It should be borne in mind that lower abdominal pain or fainting may be evidence of an ectopic (ectopic) pregnancy.

Eskinor-F does not protect against sexually transmitted infections.

The effectiveness of the drug may decrease in women with gastrointestinal diseases or overweight, so they should be especially careful.

Influence on the ability to drive vehicles and complex mechanisms

If dizziness appears, it is recommended to refrain from performing work requiring increased concentration of attention and speed of psychomotor reactions, including driving or other mechanisms.

Application during pregnancy and lactation

The use of Eskinor-F is contraindicated during pregnancy and lactation.

If conception occurred while taking levonorgestrel, then you should not fear an adverse effect on the fetus.

If you need to use emergency contraception during lactation, you must stop breastfeeding within the first 24 hours after taking the pill.

Pediatric use

The use of Eskinor-F at the age of 16 years is contraindicated.

The use of the drug in girls under 16 years old is allowed only after consulting a gynecologist in exceptional cases (including rape). After emergency contraception, it is recommended to undergo a repeated gynecological examination.

For violations of liver function

The use of Eskinor-F is contraindicated in severe liver failure.

Pills should be taken with caution in women with liver or biliary tract diseases, jaundice (including a history).

Drug interactions

When applied simultaneously with Eskinor-F:

• primidone and other barbiturates, phenytoin, amprenavir, lansoprazole, oxcarbazepine, tacrolimus, nevirapine, topiramate, tretinoin, carbamazepine, St. therapy with each of the listed agents may decrease the contraceptive effect of the drug;
• inducers of microsomal liver enzymes: accelerate the metabolism of levonorgestrel;
• hypoglycemic agents, anticoagulants (phenindione, coumarin derivatives): the therapeutic effect of these drugs decreases. Therefore, it is not recommended to combine them with levonorgestrel without consulting a doctor;
• glucocorticosteroids: their plasma concentration increases;
• cyclosporine: the risk of cyclosporine toxicity is increased;
• ulipristal preparations: it is not recommended to use levonorgestrel with ulipristal preparations due to the possible decrease in the clinical effect of the latter.

Analogs

Lalinola, Mirena, MODELL 911, Postinor, Postiplaniya, Escapel are analogues of Eskinor-F.

Terms and conditions of storage

Keep out of the reach of children.

Store at temperatures up to 25 ° C, protected from moisture and light.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Escinor-F

Reviews about Eskinor-F are mostly positive.

But cases are described when, after unprotected sexual intercourse, against the background of timely administration of the drug, an unplanned conception occurs. Presumably, they are due to the individual characteristics of the patient's body.

Price for Eskinor-F in pharmacies

The price for Eskinor-F has not been set due to the lack of the drug in the pharmacy chain.

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!